Business Context and Reporting Period
Company: Alpha Tau Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2026 (Specific date: February 24, 2026)
Context: The filing reports a significant regulatory milestone where the Company received Japanese marketing approval for its product, Alpha DaRT®, for the treatment of unresectable locally advanced or locally recurrent head and neck cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report regarding a specific corporate event and does not contain financial statements or quantitative financial data.
Material Changes
Regulatory Approval: The primary material change is the receipt of marketing approval in Japan for Alpha DaRT®. This expands the potential commercial geography for the Company's lead product in the specified indication.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the approval but does not include forward-looking guidance, financial outlook, or specific risk factors within the body of this report.
Unusual Items: None reported beyond the regulatory approval event.
Investor Verification Checklist
- Verify the specific terms and scope of the Japanese marketing approval for Alpha DaRT® in the attached press release (Exhibit 99.1).
- Confirm the timeline for commercial launch and reimbursement status in Japan.
- Review the Company's most recent Form 20-F or quarterly reports for current financial health, as this filing contains no financial data.
- Assess the potential revenue impact of the Japanese market relative to the Company's total addressable market.